BioSpace News Archive

Halozyme Therapeutics, Inc., will participate in the Bank of America Securities 2020 Healthcare Conference.

Genelux Corporation, a privately-held, clinical-stage immunotherapy company, today announced the outcome of a Type C meeting with the U.S. Food and Drug Administration (FDA) held on M

This DOD-funded initiative will assess the role of home-based continuous biosensor data and AI analytics in addressing the global COVID-19 crisis.

UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced financial results for the first quarter ended March 31, 2020 and provided an overview of the Company’s recent developments.

Applied DNA Sciences, Inc. (NASDAQ: APDN), announced today it plans to release financial results for its fiscal 2020 second quarter ended March 31, 2020 after market close on Thursday, May 14, 2020. In conjunction with the release, the Company has scheduled a conference call at 4:30 p.m. Eastern Time that will also be broadcast live over the Internet. What: Applied DNA’s Fiscal 2020 Second Qu

Cortexyme to Present at the BofA Securities 2020 Health Care Conference on May 13, 2020 -- Presentation to be webcast on Cortexyme’s website SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE )-- Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat what it believes to be a key underlying cause of Alzheimer’s and other degenerative diseases, today announced Casey Lynch

ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced that clinical data evaluating Gencaro™ (bucindolol hydrochloride) as a potential treatment for atrial fibrillation (AF) in patients with heart failure (HF)

ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef calves, will report unaudited financial results for the quarter ended March 31, 2020 after the market closes on Wednesday, May 13, 2020.

In an effort to further mitigate risk from the novel coronavirus to critical health-care workers and the community, a Kansas City-area health system has deployed Black & Veatch’s first portable Rapid Modular Health System (RaMHS) structure.

More than ever before, collaboration and efficiency are critical in scientific research as the world seeks solutions to the Coronavirus Pandemic. In recent weeks, pharma, financial and federal organizations made deliberate shifts, changing several facets of clinical trials to allow research to proceed at an unprecedented pace.